Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpelisib + exemestane
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of alpelisib, a phosphatidylinositol 3-kinase (PI3K) inhibitor that specifically targets the p110α catalytic subunit, and exemestane, an aromatase inhibitor. This combination is used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, particularly in patients who have progressed on prior therapies.
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on alpelisib + exemestane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpelisib + exemestane.